Osprey raises $11M for protein therapeutics
Osprey Pharmaceuticals U.S.A. has raised $11 million in a first round of funding, according to VentureWire. The San Francisco company’s protein therapeutics treatment targets kidney disease. Burrill & Co. led the round, with participation from BDC Venture Capital, GeneChem Therapeutics Venture Fund, Novo Nordisk Biotech Fund, Western Technology Seed Investment Fund and Yasuda Enterprise Development.
Next Story: Pathwork Diagnostics raises $20M for cancer diagnostic tests
Previous Story: Space Pencil raises $800,000 for web analytics
About the Author, Anthony Ha
Anthony is a senior editor at VentureBeat, as well as its reporter on media, advertising, and social networks. Before joining the site in 2008, Anthony worked at the Hollister Free Lance, where he won awards from the California Newspaper Publishers Association for breaking news coverage and writing. He attended Stanford University and now lives in San Francisco. Reach him at anthony@venturebeat.com. (All story pitches should also be sent to tips@venturebeat.com) You can also follow Anthony on Twitter.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
